The partnership aims at the discovery and development of novel therapeutics for neurodegeneration mediated by a disease-specific protein.
As a part of the agreement, Galenea will leverage synaptic transmission platform technology to address synaptic dysfunction in neurodegenerative diseases. Eisai will make an up-front payment and milestone payments throughout the program.
Galenea president and CEO Mark Benjamin said the collaboration, which is focused on a single, highly implicated target in neurodegeneration, has been crafted to take advantage of the company’s unique approach.
"We are thrilled to be working with Eisai, and we see enormous potential in this program and partnership," Benjamin added.
Galenea’s approach deals with disease mechanism, using MANTRA; predictive animal models, using integrated behavioral assessment and EEG measures; and clinical biomarkers, using translational EEG measures elicited by behavioral tasks in the clinic.
The MANTRA system is the high throughput screening system for directly identifying modulators of synaptic transmission in primary neurons, according to Galenea.